NCT01652560

Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: LiNanlin,Ph.D, Chief Physician,Clinical Professor · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

\- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.

Conditions

• Breast Cancer
• Bevacizumab
• Neoadjuvant Chemotherapy
• Molecular Targeted Therapy

Interventions

Type	Name	Description
DRUG	bevacizumab	The patients will be treated with Avastin combined neoadjuvant chemotherapy

Timeline

• Start date: 2012-06-01
• Primary completion: 2014-06-01
• Completion: 2014-09-01
• First posted: 2012-07-30
• Last updated: 2012-07-30

Locations

1 site across 1 country: China